Immunoglobulin may benefit those with COVID vaccine-related blood clotsHigh doses of intravenous immunoglobulin (IVIG) in conjunction with an anticoagulant were associated with resolved vaccine-induced immune thrombotic thrombocytopenia (VITT) in three patients, according to a report yesterday in the New England Journal of Medicine.VITT occurs when antibodies attack protein factor 4 (PF4), leading to blood clumping and clots.The patients, one woman and two men, were 63 to 72 years old and received the AstraZeneca/Oxford COVID-19 vaccine in Canada from Mar 31 to Apr 13. (At that time, Canada restricted AstraZeneca use to those older than 55 because VITT is mostly observed in younger populations.)Two patients with no comorbidities were